Bristol-Myers Squibb Statement on Muraglitazar, an Investigational Oral Treatment for Type 2 Diabetes
Posted on: Thursday, 22 December 2005, 09:00 CST
PRINCETON, N.J., Dec. 22 /PRNewswire-FirstCall/ -- As previously disclosed, Bristol-Myers Squibb Company agreed to begin discussions with Merck & Co., Inc. to terminate the collaborative agreement for muraglitazar, the company's investigational oral medicine for the treatment of type 2 diabetes.
The companies have reached a mutually acceptable termination agreement, with all rights to muraglitazar returning to Bristol-Myers Squibb as of December 21, 2005. The termination agreement also covers the reversion to Bristol-Myers Squibb of a back-up compound to muraglitazar.
Bristol-Myers Squibb is continuing discussions with the U.S. Food and Drug Administration (FDA) and is considering a range of options including conducting additional studies or terminating further development of muraglitazar. The additional studies could take approximately five years to complete.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
This press release contains certain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 regarding a product in development that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainty of the success of the research and development activities; decisions by regulatory authorities regarding whether and when to approve any new drug application for a product candidate that may result from the research, as well as their decisions regarding labeling and other matters that could affect the commercial potential of such product candidate; and competitive developments. A further list and description of risks and uncertainties can be found in the Bristol-Myers Squibb's Annual Report on Form 10-K for the fiscal year ended December 31, 2004, and in its reports on Form 10-Q and Form 8-K. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Bristol-Myers Squibb Company
CONTACT: Media: David M. Rosen, +1-609-252-5675, pager:+1-866-308-4484, david.m.rosen@bms.com, or Investors: John Elicker,+1-212-546-3775, john.elicker@bms.com, both of Bristol-Myers Squibb Company
Web site: http://www.bms.com/
Source: PRNewswire-FirstCall
Related Articles
- Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program
- Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma
- ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
- Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
- Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
- Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds
- Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds
- Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan
- Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Discover and Develop Novel Oncology Compounds
- Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (Efavirenz 600 Mg/ Emtricitabine 200 Mg/ Tenofovir Disoproxil Fumarate 300 Mg) in Canada
 |
 |
User Comments (0)
RSS Feeds